Letter re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

We read with great interest the recently published article by Persano et al [ [1] Persano M. Rimini M. Tada T. et al. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients. Eur J Cancer. 2023; 189112933 Abstract Full Text Full Text PDF PubMed Scopus (3) Google Scholar ]. The retrospective study predominantly compared the overall survival (OS) of progressive hepatocellular carcinoma (HCC) patients receiving different second-line therapies after first-line lenvatinib or atezolizumab plus bevacizumab. The authors demonstrated significantly improved survivals of patients undergoing second-line transarterial chemo-embolization (TACE) in comparison with second-line sorafenib. Moreover, lenvatinib is considered as the systemic therapy that provides the longest OS after failure of first-line atezolizumab plus bevacizumab, and immunotherapy as the optimal second-line systemic therapy after failure of first-line lenvatinib. Herein, we would like to raise the following comments: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patientsEuropean Journal of CancerVol. 189PreviewThe aim of this retrospective proof-of-concept study was to compare different second-line treatments for patients with hepatocellular carcinoma and progressive disease (PD) after first-line lenvatinib or atezolizumab plus bevacizumab. Full-Text PDF Open AccessResponse to letter entitled Re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patientsEuropean Journal of CancerVol. 192PreviewDear Editor, Full-Text PDF